Management of cancer treatment-induced bone loss (Q38090917)

28 August 2017

title

Management of cancer treatment-induced bone loss (English)

1 reference

28 August 2017

Robert E Coleman

1

1 reference

28 August 2017

Emma Rathbone

series ordinal

2

1 reference

28 August 2017

Janet E Brown

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

19 March 2013

1 reference

Nature Reviews Rheumatology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

365-374

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Perspective. How many women have osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Osteoporosis in men: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

FRAX(®) with and without bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Changes to adjuvant systemic therapy in breast cancer: a decade in review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

A pooled analysis of vitamin D dose requirements for fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Vitamin D and Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Denosumab in patients with cancer—a surgical strike against the osteoclast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The economic burden of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Blockade of testicular and adrenal androgens in prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Impact of surgical and medical castration on serum testosterone level in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

The relationship between daily calcium intake and bone mineral density in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Effects of bone-targeted agents on cancer progression and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Risk of fracture after androgen deprivation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

ACP Journal Club. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2013.36

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23507900

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Who are candidates for prevention and treatment for osteoporosis?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23507900

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2013.36

1 reference

Dimensions Publication ID

28 August 2017

1027882595

0 references

1 reference